# paper.pdf ## Metadata - PDFFormatVersion=1.6 - Language=en - IsLinearized=true - IsAcroFormPresent=false - IsXFAPresent=false - IsCollectionPresent=false - IsSignaturesPresent=false - CreationDate=D:20260702094409+05'30' - Creator=LaTeX with hyperref package - ModDate=D:20260702094455+05'30' - Producer=Acrobat Distiller 26.0 (Windows) - Title=Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy - Custom.WPS-ARTICLEDOI=10.1002/alz.71652 - Custom.WPS-JOURNALDOI=10.1002/(ISSN)1552-5279 - Custom.WPS-PROCLEVEL=3 - xmp:createdate=2015-08-18T08:05:36+05:30 - xmp:modifydate=2016-06-21T14:17:29-04:00 - xmp:metadatadate=2016-06-21T14:17:29-04:00 - pdf:producer=Acrobat Distiller 9.0 (Windows) - pdfx:wps-articledoi=10.1002/alz.71652 - pdfx:wps-journaldoi=10.1002/(ISSN)1552-5279 - pdfx:wps-proclevel=3 - jav:journal_article_version=VoR - prism:doi=10.1002/alz.71652 - dc:format=application/pdf - dc:title=Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy - xmpmm:documentid=uuid:840b6e7c-1c02-38d9-9b30-7caf7d04bfff - xmpmm:instanceid=uuid:378477bd-0e0d-3242-aa0f-63e4d56c55c9 ## Contents ### Page 1 Received: 24 November 2025 Revised: 8 May 2026 Accepted: 6 June 2026 DOI: 10.1002/alz.71652R E S E A R C H A R T I C L E Unveiling the procoagulant state in Alzheimer’s disease: A novel PET imaging strategy Carlos Ceron1 Marta Casquero-Veiga1,2 Nicolás Lamanna-Rama1,3Irene Fernández-Nueda1 Alberto Fernández-Pena1 Nancy Olazagoitia1Gorka Sobrino1 Aitor Herraiz4 María Isabel González1María Muñoz-Hernando1,4 Alejandro Ruperti-Repilado5Eduardo Romero-Sanz6 Miguel Ángel Morcillo6 Carlos Pérez-Medina1Maria Angeles Moro1 Gonzalo Villaverde5 Jorge Rubio5Jose Fernandez-Ferro1,2 Manuel Desco1,7,8,9 Fernando Herranz4,10Beatriz Salinas1,7,9,11 Valentin Fuster1,12 Marta Cortes-Canteli1,31Centro Nacional de Investigaciones Cardiovasculares (CNIC), C. Melchor Fernández Almagro, Madrid, Spain 2Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain 3Centro de Neurociencias Cajal – Consejo Superior de Investigaciones Científicas (CNC-CSIC), Alcalá de Henares, Madrid, Spain 4Instituto de Química Médica – Consejo Superior de Investigaciones Científicas (IQM-CSIC); C. Juan de la Cierva, Madrid, Spain 5MatNaBio group, Dpto. de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Madrid, Spain 6Medical Application of Ionising Radiations Unit, Centre for Energy, Environmental and Technological Research (CIEMAT), Madrid, Spain 7Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), C. Dr. Esquerdo, Madrid, Spain 8Dpto. de Bioingeniería, Escuela Politécnica Superior, Universidad Carlos III de Madrid (UC3M), Leganés, Madrid, Spain 9Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Av. Monforte de Lemos, Madrid, Spain 10Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain 11Dpto. de Ciencia e Ingeniería de Materiales e Ingeniería Química, Escuela Politécnica Superior, Universidad Carlos III de Madrid (UC3M), Leganés, Madrid, Spain 12Icahn School of Medicine at Mount Sinai, New York, New York, USACorrespondenceMarta Cortes-Canteli, Centro de Neurociencias Cajal – Consejo Superior de Investigaciones Científicas (CNC-CSIC), Av. Leon 1, Alcalá de Henares 28805, Spain. Email: marta.casquero@iis-fjd.es Marta Casquero-Veiga, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD); Av. de los Reyes Católicos 2, Madrid 28040, Spain. Email: marta.cortes@csic.es Carlos Ceron and Marta Casquero-Veiga are co-first authors.Abstract INTRODUCTION: A subset of Alzheimer’s disease (AD) patients exhibits a procoag- ulant state that remains undiagnosed despite available treatments. We developed positron emission tomography (PET) strategies to in vivo detect cerebral microthrombi in TgCRND8 mice.METHODS: PET was performed with a fibrin-binding probe (FBP) in TgCRND8 and wild-type mice using a zirconium-89–radiolabeled and a click-chemistry pre-targeted gallium-68 radiotracer. Platelet content was assessed in post mortem brain tissue from AD patients and TgCRND8 mice, and evaluated by PET using a CD41 pre-targeted gallium-68 nanoradiotracer. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2026 The Author(s). Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.Alzheimer’s Dement. 2026;22:e71652. wileyonlinelibrary.com/journal/alz 1 of 21https://doi.org/10.1002/alz.71652 ### Page 2 2 of 21 CERON ET AL.Funding informationInstituto de Salud Carlos III, Grant/Award Numbers: CPII21/00007, AC20/00091, AC20/00077; BrightFocus Foundation, Grant/Award Number: A2023012F; Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033), Grant/Award Numbers: JDC2022-048922-I, RED2022-134299-T; European Union NextGenerationEU/PRTR, Grant/Award Numbers: JDC2022-048922-I, ICT2021-006950, PID2024-157521OB-I00, CNS2023-144316, PID2022-140616OB-I00, PDC2022-133493-100; Nanomedicine CSIC Hub, Grant/Award Number: ref.202180E048; Comunidad de Madrid, Grant/Award Number: S2022/BMD-7403; PTI-NEUROAGING CSIC; EU Joint Programme – Neurodegenerative Disease Research, Grant/Award Number: JPND2020-568-025; Ministerio de Ciencia, Innovación y Universidades (ES, MICIU/AEI/10.13039/501100011033), Grant/Award Numbers: RYC2023-043741-I, ICT2021-006950, PID2024-157521OB-I00, CNS2023-144316, PID2022-140616OB-I00, PDC2022-133493-100, CEX2020-001041-SRESULTS: Cerebral FBP uptake differentiated TgCRND8 from wild-type mice, partic- ularly ex vivo and with advancing age. Cerebral fibrin burden correlated with platelet content in AD patients, and elevated cerebral platelet burden in TgCRND8 mice was confirmed in post mortem tissue and in vivo by PET.DISCUSSION: Our findings support PET-based detection of AD-associated cerebral microthrombi and the development of imaging biomarkers to stratify AD patients by procoagulant status and inform personalized therapies.K E Y W O R D SAlzheimer’s disease, anticoagulant therapies, fibrin, platelets, positron emission tomography, procoagulant stateHighlights∙ Half of patients with Alzheimer’s disease (AD) exhibit a procoagulant state.∙ AD procoagulant state is characterized by abnormal fibrin deposition in the brain.∙ Fibrin burden remains undiagnosed despite available counteracting therapies.∙ Fibrin burden correlates with platelet load in the brains of AD patients.∙ Novel positron emission tomography (PET) biomarkers enable in vivo detection of cerebral microthrombi in AD mice.1 BACKGROUNDOver 55 million people are currently living with dementia worldwide1 and, with increasing life expectancy, this number is projected to reach 153 million by 2050.2 The term “dementia” encompasses several con- ditions characterized by memory and cognitive impairment, among which Alzheimer’s disease (AD) is the most common. The World Health Organization estimates that AD accounts for 60–70% of all demen- tia cases.1 AD is a complex, multifactorial neurodegenerative disorder characterized by aggregation of amyloid-β (Aβ) and phosphorylated tau in the brain parenchyma, creating senile plaques and neurofib- rillary tangles, respectively.3 Beyond these classic hallmarks, many other neuropathogenic processes contribute to AD, including neuroin- flammation, synaptic dysfunction and a strong vascular component. Together, these mechanisms create a heterogeneous scenario where single-target treatments are failing partly due to their inability to address the complex set of factors involved.4 Multifocal diagnostic and therapeutic strategies are urgently needed to handle the multifaceted nature of AD and enable personalized interventions. In 1907, Alois Alzheimer first described the neuropathology of AD and, in his original report, also noted vascular alterations (i.e., arteriosclerotic changes) in Auguste Deter’s brain.5 Today, mounting evidence implicates vascular dysfunction in AD, including intracranial atherosclerosis, cerebral amyloid angiopathy (CAA) and neurovascu- lar unit alteration leading to blood–brain barrier (BBB) disruption.6 Furthermore, AD also features an altered hemostatic response7 that affects ∼half of AD patients,6,8 promoting abnormal formation of blood clots in the brain.8–10 Aβ interacts with fibrin(ogen) — the main protein component of blood clots — hindering access of fib- rinolytic enzymes to the fibrin clot mesh and thereby stabilizing microthrombi.10–12 Aβ accumulation within cerebral blood clots has been attributed to platelets,13 the predominant cellular element of thrombi and the major source of circulating Aβ.14,15 Contact with Aβpromotes platelet activation, whose exacerbation has been repeat- edly linked to AD,16–18 leading to further increased Aβ release,19 platelet adhesion and aggregation,19,20 and ultimately contributing to CAA,19 senile plaques21 and thrombus formation.22 This pro- thrombotic milieu in AD23 drives abnormal cerebral fibrin(ogen) accumulation that lines or occludes cerebral blood vessels and extravasates into the brain parenchyma,8 exacerbating CAA,24 cere- bral hypoperfusion,25 BBB disruption,25 synaptic dysfunction,8,26,27 neurodegeneration,8 neuroinflammation,27–29 amyloid deposition9,25 and cognitive deficits,9,25 all strongly associated with AD.23,30 Despite the availability of novel anticoagulant therapies7,31 and fibrin-targeted immunotherapy32,33 that show promise in delaying AD progression in animal models, fibrin(ogen) accumulation and fibrin clot formation in the AD brain remain undiagnosed due to the lack of in vivo diagnostic strategies. This limitation is critical, as not all AD patients exhibit abnormal fibrin deposition in their brains,8 stress- ing the need for appropriate diagnostic tools to identify and stratify patients and guide therapy. Neuroimaging, especially positron emission tomography (PET), is well suited for this purpose, as it enables in vivo, non-invasive visualization of brain functional processes with excep- tional sensitivity and specificity. For example, Aβ and tau PET imaging have transformed our understanding of AD progression, guiding both clinical management and therapeutic decisions.34 However, while ### Page 3 CERON ET AL. 3 of 21RESEARCH IN CONTEXT1. Systematic review: A thorough literature review using official scientific databases (e.g., PubMed) was performed to frame this work. Half of Alzheimer’s disease (AD) patients exhibit a procoagulant state characterized by fib- rin and fibrinogen deposition in the brain and microvascu- lar dysfunction. Although counteracting therapies exist, this condition remains largely neglected due to the lack of in vivo diagnostic strategies. All relevant citations are appropriately included. 2. Interpretation: We have developed highly specific positron emission tomography (PET) biomarkers tar- geting fibrin and platelets, providing the first in vivo neuroimaging approach to detect AD’s procoagulant environment in TgCRND8 mice. Our study also offers the first quantitative evidence of increased platelet accumulation in the procoagulant human AD brain and its correlation with cerebral fibrin deposition. 3. Future directions: This manuscript expands current understanding of cerebrovascular contributions to AD and opens the door to non-invasive diagnostic approaches with tangible translational potential for patient stratification and therapeutic guidance. several PET strategies have been developed to target compo- nents of the coagulation cascade (e.g., fibrin, factor XIIIa, activated platelets35,36), these primarily detect large, well-formed clots rather than the diffuse cerebral microthrombi that characterize the AD procoagulant state. Therefore, we aim to develop a novel neuroimaging strategy to diag- nose this AD-associated prothrombotic state (i.e., cerebral fibrin depo- sition). Using TgCRND8 AD mice, which model this condition,8,9,25 we developed two pre-targeting approaches based on fibrin- and platelet- binding probes with clear translational potential. Our data provide a direct, non-invasive in vivo measure of cerebral microthrombi burden in an AD mouse model, laying the groundwork for diagnostic tools that could support patient selection for anticoagulant, antiplatelet and/or fibrin-targeted interventions aimed at slowing AD progression.2 METHODS 2.1 AnimalsTgCRND8 AD mice, kindly provided from The Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto (Canada), over- express the Swedish (KM670/671NL) and Indiana (V717F) familial AD mutations in the amyloid precursor protein under the control of the PrP gene promoter.37 Mice were kept on a mixed background (C57xC3H/C57), genotyped, and TgCRND8 AD heterozygous and non- transgenic wild-type (WT) littermates male and female mice were randomly selected throughout the experiments, as detailed below. Sample sizes were calculated empirically according to pilot imaging studies for an estimated power of 95%. Mice were housed up to five mice per cage at the National Center for Cardiovascular Research (CNIC) Comparative Medicine Unit in a dedicated vivarium, under controlled temperature and humidity condi- tions, with a 12/12 hour light-dark cycle. All experimental procedures were conducted by operators who were unaware of the experimen- tal groups, according to European Communities Council Directive 2010/63/EU, following the ARRIVE guidelines,38 and approved by the Ethics Committee in Animal Experimentation and corresponding authority (PROEX 147.7_2). Carotid Crush Injury Model – One day before PET acquisition, WT mice underwent surgical induction of a carotid crush injury to serve as positive controls (C+) for the pre-targeting imaging approaches, as previously described.39 Briefly, 70-week-old WT littermates were anesthetized with sevoflurane (5% induction, 3% maintenance in medi- cal gas). The left common carotid artery was exposed, and blood flow was occluded for 15 minutes, after which the clamp was released to restore perfusion. Immediately after surgery, animals were injected with either the corresponding pre-targeting probe or saline and pro- cessed according to the same experimental protocol used for each radiotracer, as detailed below.2.2 Radiotracer synthesisAll reagents were purchased from Merck Life Science S.L.U. (Spain) unless otherwise indicated. 2.2.1 Fibrin imaging (direct labeling) This strategy utilizes zirconium-89 (89Zr) to radiolabel a commercial Fibrin Binding Probe (FBP)40 modified with desferrioxamine B (FBP- DFO, Pepscan, The Netherlands) at the CNIC Advanced Imaging Unit radiochemistry facilities, adapting a protocol previously published.41 First, 92.5 MBq of 89Zr (PerkinElmer, USA) were placed in a 2 mL Eppendorf® tube. Then, 200 μL solution of 1 M oxalic acid and 90 μL of 2 M Na2CO3 were added to the solution, which was incubated for 3 minutes at room temperature (RT). Later, 300 μL of 0.5 M HEPES, 710 μL of FBP-DFO, and 700 μL of 0.5 M HEPES were sequentially pipetted into the reaction tube, and the solution was incubated for 60 minutes at RT and 500 rpm in the ThermoMixer® (Eppendorf Iberica S.L.U., Spain). The reaction product was transferred to a C18 SEP-PAK® light cartridge (Waters Corporation, USA), previously con- ditioned with 5 mL of EtOH and 10 mL of H2O. The cartridge was then washed with 0.5 mL of H2O to remove the free isotope, and finally the desired product was eluted and collected with 0.5 mL of EtOH. For the in vivo studies, the product was partially evaporated and reformulated in saline, maintaining 20% EtOH in the final formulation. The quality ### Page 4 4 of 21 CERON ET AL.control of the final product was performed by HPLC with a C18 col- umn and a flow rate of 0.8 mL/min (Phase A: Water + TFA 0.1%; Phase B: CH3CN; Gradient: 0–18 minutes from 0 to 100% of phase B, 18–20 minutes 100% of phase B). Once [89Zr]Zr-DFO-FBP was purified, animals were intravenously (IV) injected with 7.54 ± 2.98 MBq/mice (mean ± SD) through the tail vein, followed by imaging acquisition. [89Zr]Zr-DFO-FBP studies included five sequential PET acquisitions immediately after the radio- tracer injection (0 hour), 24, 48, 72, and 96 hours post injection. TgCRND8 AD mice and WT littermate males were used (70.77 ± 3.11- week-old, mean ± SD. 0 hour: NAD = 5, NWT = 5; 24–96 hours: NAD = 8, NWT = 8). 2.2.2 Fibrin imaging (pre-targeting) This strategy utilizes a biorthogonal reaction based on click chem- istry between FBP coupled to transcyclooctene (TCO) and a tetrazine (TZ) derivative radiolabeled with gallium-68 (68Ga), which allows an ultra-fast, covalent interaction under physiological conditions between these two chemical species (i.e., TZ and TCO). The FBP pep- tide (FHCHypY(3-Cl)DLCHIL-PXD (FBP-PXD) described by Oliveira et al.40) was in-house synthesized at the Complutense University of Madrid (UCM) by microwave-supported solid-phase peptide synthe- sis to enable temperature control, thereby reducing reaction times and improving product purity an d yield. Coupling reactions were performed with 3 equivalents (eq) of the corresponding amino acid and 3 eq of O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hex- afluorophosphate, both dissolved in amine-free dimethylformamide (AF DMF), together with 3.5 eq of N,N-diisopropylethylamine. On the other hand, Fmoc deprotection steps were carried out using 20% Piperidine in AF DMF. Standard coupling and deprotection reactions were conducted at 75◦C for 15 minutes, except for Cysteine (Cys) and Histidine units, which required milder conditions (50◦C for 20 minutes). The synthesis was initiated by coupling para-xylenediamine (PXD) to a 2-chlorotrityl resin (1.55 mmol/g) at RT. This step was performed using 3.5 eq of PXD in AF DMF with 4 eq of N,N- diisopropylethylamine, under controlled agitation for 2 hours. After each coupling/deprotection steps, washing procedure was carried out with 5 mL DCM, 5 mL DMF, and 5 mL AF DMF. Following chain assem- bly, the N-terminal amine was acetylated using 10% acetic anhydride in AF DMF, under agitation at RT for 1.5 hours. The peptide was cleaved from the resin with a TFA-based cleavage cocktail (86.5% TFA, 4.5% Triisopropylsilane, 4.5% Dithiothreitol, 4.5% Methanesulfonic acid) for 2 hours with vigorous agitation. The crude peptide was then precipi- tated in cold diethyl ether. After purification and lyophilization, 234 mg of peptide was obtained, corresponding to a 48% overall yield. Addi- tionally, a non-functional FBP isomer that differs in the chirality of one cysteine (i.e., DCys-FBP), preventing the peptide cyclization crucial for fibrin binding,42 was identically synthesized and used as negative control of the fibrin pre-targeting probe (C-DCys). Once synthesized, FBP and DCys-FBP were coupled to TCO- PEG4-NHS (TCI Europe N.V., Belgium) under an argon atmosphere using a 1:1 stoichiometric ratio. Both components were dissolved in anhydrous DMF in argon-purged vials. To the peptide solu- tion, 20 eq of N,N-diisopropylethylamine were added to deproto- nate the PXD amine, and the mixture was stirred for 1 h RT. TCO-PEG4-NHS was then added dropwise, and the reaction was allowed to proceed overnight at RT under continuous stirring. The crude product was precipitated with cold diethyl ether, purified, and lyophilized. Similarly, TZ was coupled with 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; following a protocol developed at UCM, and radiolabeled at CNIC radiochemistry using 68Ga obtained from a germanium-68/68Ga generator (IRE Elit Radiopharma, Belgium). First, we placed 400 MBq of [68Ga]GaCl3 (0.05 – 0.1 M) in a 1.5 mL Eppendorf® tube. Then, 20 μL of TZ-DOTA (5 mg/mL) were added to the tube, followed by 200 μL of 1 M HEPES. The solution was incubated during 20 minutes at 95◦C and 500 rpm in a ThermoMixer®. The reaction product was transferred to a C18 SEP-PAK® light cartridge (Waters Corporation), previously condi- tioned with 5 mL of EtOH and 5 mL of H2O. The cartridge was then washed with 5 mL of H2O to remove the free isotope, and finally the desired product was eluted and collected with 0.3 mL EtOH. For the in vivo studies, the product was partially evaporated and reformulated in saline, maintaining 20% EtOH in the final formulation. Quality control of the final product was performed by HPLC with a C18 column and a flow rate of 0.8 mL/min (Phase A: Water + TFA 0.1%; Phase B: CH3CN; Gradient: 0–18 minutes from 0 to 100% of phase B, 18–20 minutes 100% of phase B). The day before imaging acquisition, animals were IV injected through the tail vein with FBP-TCO (100 μg/mouse). The next day, animals were IV injected with 12.08 ± 0.64 MBq/mice (mean ± SD) of [68Ga]Ga-DOTA-TZ through the tail vein and left for 2 hours before PET imaging. Experimental groups of 77.43 ± 13.28-week-old (mean ± SD) mice included a total of 14 AD (nine females, five males), 15 WT (eight females, seven males) and 14 AD animals injected with the non-functional DCys-FBP-TCO (C-DCys; six females, eight males) as negative controls. 2.2.3 Platelet imaging (pre-targeting) The platelet probe consisted of Thrombo-tag,43 a PET radiotracer based on in vivo click chemistry between a specific anti-platelet antibody (i.e., anti-CD41) and new-generation 68Ga-labeled nanora- diotracers: iron oxide nanoparticles (IONP) doped with 68Ga. For func- tionalization of the anti-CD41 antibody (#14-0411-85, eBioscience™, Thermo Fisher Scientific, USA) with TCO, 0.4 mg/mL of the anti-CD41 antibody were mixed with 0.18 mg/mL 0.1 M Na2CO3 in phosphate buffered saline (PBS) 1× (pH ∼ 9) and 0.02 mg/mL of TCO-NHS ester. The reaction was stirred at RT for 60 minutes, purified by ultrafiltration (100 kDa filters), and the retentate diluted with PBS to a concentra- tion of 400 μg/mL. This protocol was also used to functionalize an immunoglobulin (Ig) G1 isotype control (#14-4301-85, eBioscience™, ### Page 5 CERON ET AL. 5 of 21Thermo Fisher Scientific, USA), used as negative control of the platelet pre-targeting probe (C-IgG). The radiosynthesis of [68Ga]Ga-IONP-TZ was carried out before each imaging study, at the CNIC and Centre for Energy, Environmental and Technological Research (CIEMAT) radiochemistry facilities. Briefly, IONP-TZ synthesis involved mixing the nanoparticle precursors (FeCl3, sodium citrate and [68Ga]GaCl3) with hydrazine, and the resulting mix- ture was stirred under microwave at 120◦C for 10 minutes. After that, the [68Ga]Ga-IONP solution was purified by ultrafiltration, and EDC and sulfoNHS (Thermo Fisher Scientific) were added to the purified product. This solution was incubated at RT and 650 rpm for 30 min- utes, and later purified using 30 kDa Amicon filters. The nanoparticles were resuspended in HEPES buffer (pH 8) and 0.2 mg/mL of ben- zylamino TZ dissolved in dimethylsulfoxide (DMSO) was added. The solution was incubated at RT and 650 rpm for 45 minutes to form the [68Ga]-IONP-TZ, ultrafiltrated and resuspended in PBS. The day before the PET study, animals were IV injected through the tail vein with the antibody anti–CD41-TCO (70 mg/kg). The next day, animals were IV injected with 9.23 ± 1.51 MBq/mice (mean ± SD) of [68Ga]Ga-IONP-TZ through the tail vein, and PET acquisition was per- formed 2 hours post-injection. Experimental groups of 79.10 ± 16.63- week-old (mean ± SD) mice included a total of 15 AD (11 females, four males), 18 WT (11 females, seven males), and 11 AD animals injected with the non-specific IgG1-TCO probe (C-IgG; six females, five males) as negative controls.2.3 Imaging acquisition and processingImaging studies were performed under isoflurane anesthesia (5% induction, 3% maintenance in medical air) in the facilities of the Distributed Biomedical Imaging Network (ReDIB, Spain) at CNIC. Tem- perature control and respiration (through a respiratory pad) were registered along the imaging session. In each imaging study, the whole body of the animal was scanned for 40 minutes: first acquiring a 10- minute computerized tomography (CT) scan, and then a 30-minute PET image. Decay and dead time corrections were applied. Fibrin imaging (direct labelling) using [89Zr]Zr-DFO-FBP and platelet imaging (pre-targeting) using Thrombo-tag (i.e., anti–CD41- TCO + [68Ga]Ga-IONP-TZ) were acquired with a dedicated small animal nanoScan® PET/CT scanner (Mediso, Hungary). CT studies were reconstructed with an isotropic voxel size of 0.14 mm. PET images were reconstructed using a 3D-OSEM algorithm with four iterations and six subsets, and isotropic voxel size of 0.4 mm3 and were spatially normalized to a reference mouse brain atlas44 using a rigid registration algorithm based on mutual information available at the Multimodal Workstation software (BIIG, Spain).45 Fibrin imaging (pre-targeting) acquisitions using FBP-TCO +[68Ga]Ga-DOTA-TZ were obtained with the X-CUBE® micro-CT andɣ-CUBE® micro-PET scanners (Molecubes NV, Belgium). CT studies were reconstructed with an isotropic voxel size of 0.1 mm3. PET images were reconstructed using a 3D-OSEM algorithm with 10 iterations and isotropic voxel size of 0.4 mm3 and were registered to the same brain atlas44 using a rigid registration algorithm based on mutual information in FSL (Oxford University, UK).46 Each registered PET image was smoothed using an isotropic Gaus- sian filter with Full Width at a Half Maximum of 2.5 times the voxel size. For intensity normalization, [89Zr]Zr-DFO-FBP images were ini- tially subjected to an iterative histogram-based normalization47 to provide an objective basis for comparing tracer uptake across differ- ent time points (0, 24, 48, 72, and 96 hours post-injection). After that, the 24-hour time-point was chosen for subsequent analyses since it revealed the largest differences between AD and WT groups. All scans were then analyzed using a reference cluster method,48 specifically designed for situations where a baseline bias in the data is expected (e.g., higher uptake in the AD group), correctly accounting for this bias and preventing underestimation of true group differences. Smoothing and normalization steps were performed by means of in-house scripts made in MATLAB R2023a (MathWorksInc., USA). PET data were analyzed using hypothesis-driven and exploratory strategies. On the one hand, classical regions-of-interest (ROIs) analy- ses were performed. ROIs were defined by masks segmented from the reference mouse brain atlas44 for (coordinates from Bregma): whole brain (4.28 mm to -8.24 mm), cerebellum (-5.34 mm to -8.24 mm), cortex (2.96 mm to -4.84 mm), hippocampus (-1.58 mm to -2.92 mm), striatum (1.4 mm to -1.58 mm), subcortex (1.34 mm to -2.92 mm), and thalamus (-0.82 mm to -2.92 mm); and directly applied on the pre- viously preprocessed PET images to obtain their mean uptake value. On the other hand, a voxel wise exploratory approach was conducted to identified differences in brain uptake between AD and WT groups without a predefined hypothesis. See the 2.8. Statistical analyses section for details.2.4 Biodistribution studiesNecropsies were performed immediately after each pre-targeting PET acquisition. The activity in each brain sample was measured on a dedicated gamma-counter (PerkinElmer, USA) and expressed as per- centage of the injected dose per gram of tissue (%ID/g). The sample size of the biodistribution data does not strictly coincide with that of imag- ing studies because, on the rare occasions an error occurred during PET acquisition and images could not be recovered, brain samples were still collected for gamma-counter measuring, maintaining the same uptake periods. Therefore, fibrin pre-targeting experimental groups included 17 AD (eight females, nine males), 16 WT (nine females, seven males) and 16 C-DCys (seven females, nine males), while platelet pre-targeted groups comprised 16 AD (12 females, four males), 18 WT (13 females, five males), and 11 C-IgG (six females, five males).2.5 Brain samplesPost mortem frontal cortex samples and data from AD patients included in this study were provided by the Biobank Banco de Tejidos CIEN – BT- CIEN (PT17/0015/0014), with the appropriate approval of the Ethics ### Page 6 6 of 21 CERON ET AL.and Scientific Committees (CEI PI 91_2019 & CEI PI 14_2023). BT- CIEN is integrated in the Spanish National Biobanks Network and samples were processed following standard operating procedures. The cohort (N = 39) comprised females (85%) and males (15%) with a mean ± SD age of 87.4 ± 5.7 years and an average post mortem inter- val of 4.4 hours (Table S1 of supporting information). Blocks of frozen frontal cortex samples were sliced by cryostat and collected in tubes for Western blot (WB) analysis, as previously described.8 An addi- tional subset of these blocks was fixed in 0.5% paraformaldehyde (PFA) for fibrin immunostaining. Additionally, slides containing paraffin- embedded frontal cortex tissue from a subset of these patients (N = 11) were obtained from BT-CIEN for subsequent immunohistochemistry assays. Mice were anesthetized and transcardially perfused with a hep- arin/saline solution. Brains were removed and one hemisphere was dissected into cortex and hippocampus and directly frozen at −80◦C for WB analysis, and the other hemisphere was fixed in PFA for subsequent staining procedures.2.6 WBProtein extraction for WB analyses was performed with slight modi- fications from previously described protocols.8 Human frozen tissue collected in tubes was homogenized in 1:5 (g:ml) of PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and protease inhibitor cocktail (Roche-11836170001) using the Tis- sueRuptor II (Qiagen, USA) and minimum speed for 5-7 seconds. The homogenate was centrifuged at 4◦C at 10,000 × g for 10 minutes, and the supernatant (soluble fraction) was transferred to a different tube. The pellet was homogenized in 3 M urea, for 2 hours at 37◦C and cen- trifuged at 14,000 × g for 15 minutes. Supernatant was collected in a different tube, and the insoluble (fibrin containing) pellet was resus- pended in reducing sodium dodecyl sulfate loading buffer at 65◦C for 15 minutes. The amount of protein in the soluble fraction was quantified with a Bicinchoninic Acid kit for protein determination, following manu- facturer’s instructions (Thermo Fisher Scientific). Equal amounts of soluble (40 μg) or insoluble (10 μL) protein from each sample were run on 4%-20% gradient polyacrylamide Criterion gels (Bio-Rad, USA) under reducing conditions and then transferred to polyvinylidene flu- oride membranes. Membranes were blocked with 3% bovine serum albumin or 5% non-fat milk. Blots containing soluble protein extracts were cut by the 75 kDa marker and incubated overnight at 4◦C in the same blocking solution with the following primary antibodies: rat monoclonal anti-CD41 antibody (upper half; MWReg30, 1:1000, BD Pharmingen, USA) and rat monoclonal anti-tubulin antibody (lower half; YOL1/34, 1:5000, Abcam, UK). Blots containing insoluble protein extracts were incubated with mouse monoclonal anti-fibrin antibody (59D8, 1:1000, Thermo Fisher Scientific) under the same conditions. The following day, membranes were incubated with the correspond- ing secondary antibodies coupled with horseradish peroxidase (HRP; goat polyclonal anti-mouse antibody, 1:1000, Agilent Dako, Denmark or goat polyclonal anti-rat antibody, 1:5000, Thermo Fisher Scien- tific). Incubation was followed by development with either ECL reagent Immobilon Classico Western HRP substrate or Immobilon Forte West- ern HRP Substrate, as needed. Direct digital images were acquired with the Image Quant LAS 4000 mini (GE Healthcare, USA). After develop- ment, membranes containing insoluble protein extracts were stripped with Restore PLUS WB Stripping Buffer (Thermo Fisher Scientific) and incubated with rat monoclonal anti-tubulin antibody (YOL1/34, 1:5000, Abcam), followed by a secondary goat polyclonal anti-rat (1:5000, Thermo Fisher Scientific). Cortical and hippocampal frozen samples from 60- to 95-week-old mice six AD (four females, two males) and six WT (six females) followed the same protocol as described above for soluble protein extracts from human frozen brain blocks, except that the following primary antibodies were used: rabbit polyclonal anti-CD41 antibody (1:250, Proteintech, USA), and rat monoclonal anti-tubulin antibody (YOL1/34, 1:5000, Abcam). Corresponding secondary antibodies included goat polyclonal anti-rabbit antibody (1:1000, Agilent Dako) and goat poly- clonal anti-rat (1:5000, Thermo Fisher Scientific). As appropriate, human or mouse platelets lysates and in vitro human fibrin clots8 were run in parallel as positive controls. Tubulin served as loading control given its ubiquitous expression. Densitometry quan- tification analysis of three different WB experiments was carried out using the Fiji tool “Gel Analysis”.2.7 Brain stainingHuman brain staining—Human frontal cortex 5-μm paraffin-embedded sections were subjected to deparaffination and heat induce epitope retrieval with Tris-ethylenediaminetetraacetic acid (EDTA) buffer (pH 9) and staining were performed by the CNIC Histopathology Core using an automated processing system. Endogenous peroxidase was quenched by incubation with 3% H2O2 and endogenous antigens blocked with 5% bovine serum albumin and 10% fetal bovine serum. A rabbit polyclonal anti-CD41 antibody (1:200, Novus Biologicals, USA) was used and processed following the EnVision+ System HRP Labelled Polymer Anti-Rabbit (Agilent Dako) protocol. Diaminobenzidine was used for visualization. Sections were counterstained with hematoxylin and scanned with the Axio Scan Z1® (Carl Zeiss, Germany). The total number of CD41-positive platelets was quantified using the Fiji macro “Analyze Particles” (N = 11; mean area quantified per section = 286 mm2). For fibrin/CD41 co-staining, fibrin immunohistochemistry was performed as previously described,8 with the key modification that tissue was fixed in 0.5% PFA (instead of 4% PFA plus proteinase K treatment), because subsequent CD41 was not compatible with proteinase K. Briefly, a subset of frozen human post mortem AD tissue was fixed in 0.5% PFA, cryoprotected in 30% sucrose/PFA and sec- tioned on a cryostat. Free-floating 20-μm sections were incubated in methanol/H2O2 to quench endogenous peroxidase activity, blocked in Tris buffer with 2% donkey:horse serum (1:1), and incubated overnight with a monoclonal anti-fibrin antibody (59D8, 1:1000, Thermo ### Page 7 CERON ET AL. 7 of 21Fisher Scientific). Sections were then incubated with ready-to-use EnVision+ System HRP Labelled Polymer Anti-Mouse (Agilent Dako) and developed with ImmPACT DAB Peroxidase Substrate (Vector Labs). For subsequent Vector Blue labeling, sections were re-blocked and incubated overnight at 4◦C with a rabbit polyclonal anti-CD41 (1:500, Novus Biologicals, USA). The following day, sections were incu- bated with alkaline phosphatase-conjugated ImmPRESS-AP Polymer Anti-Rabbit IgG reagent and developed with Vector Blue substrate (Vector Laboratories) for 15 minutes, dehydrated, cleared in histoclear, coverslipped with fluoromount and scanned with the Axio Scan Z1® (Carl Zeiss). Mouse brain staining—The contralateral cerebral hemisphere from the animals used for the WB experiments was fixed in 4% or 0.5% PFA. After 24 hours of fixation at 4◦C, samples were cryoprotected in a solution of PFA with 30% sucrose, and frozen at -80◦C until sliced. Free-floating 20-μm cryostat brain sections were obtained and kept frozen in cryoprotectant buffer until use. The 4% PFA-fixed floating sections (three sections/mouse) from seven AD (six females, one male) and six WT (five females, one male) 95-week-old mice were subjected to immunohistochemistry, as previously described.25 Briefly, endoge- nous peroxidase activity was quenched by incubating the sections for 15 minutes in PBS/3% H2O2. After rinsing, non-specific binding was blocked by incubating the tissues in PBS containing 0.1% Triton X-100, 3% bovine serum albumin, 0.1 M lysine and 5% goat serum (Vector Laboratories, USA). Sections were incubated overnight at 4◦C with a rat monoclonal anti-CD41 (MWReg30, 1:500, BD Pharmingen, USA) followed by several washes and incubation for 1 h with a biotinylated goat anti-rat secondary antibody (1:1000, Vector Laboratories). Sec- tions were incubated for 1 h with the ImmunoPure Ultra-Sensitive ABC Peroxidase Staining kit (Thermo Fisher Scientific), developed using the diaminobenzidine method, rinsed, mounted, dehydrated, cleared in xylene and coverslipped using DePex mounting medium. Counter- staining with 0.5% Thioflavin S was performed to identify Aβ. Slides were scanned with the Axio Scan Z1® (Carl Zeiss) and CD41-positive cells were visually identified and counted using the NanoZoomer Dig- ital Pathology software (Hamamatsu, Japan) across the entire cortex and hippocampus of AD and WT mice (N = 7 AD and N = 6 WT mice; mean area quantified per section = 6.26 mm2). For fibrin/CD41 co-staining, we followed the same protocol described above for CD41, except that mouse brain hemispheres were fixed in 0.5% PFA (fibrin(ogen) immunolabeling is suboptimal in 4% PFA-fixed tissue). 0.5% PFA-fixed floating sections (three sec- tions/mouse) from three AD and three WT 70-week-old males were incubated with a rabbit polyclonal anti-fibrin(ogen) antibody (1:500, gift from Dr. J. L. Degen, Cincinnati, OH, USA) followed by a biotinylated goat anti-rabbit secondary antibody (1:1000, Thermo Fisher Scientific). For subsequent Vector Blue labeling, the same procedure described above for the human tissue was applied, using a rat monoclonal anti- CD41 antibody (MWReg30, 1:500, BD Pharmingen, USA) and the ImmPRESS-AP Polymer Anti-Rat IgG reagent. Slides were scanned with the Axio Scan Z1® (Carl Zeiss). For triple immunofluorescence (6E10/fibrin(ogen)/CD41), 0.5% PFA-fixed-free-floating sections (three sections/mouse) from four AD (two females, two males) and four WT (two females, two males) 70- week-old mice were blocked in PBS containing 0.25% Triton X-100 and 3% normal goat serum and incubated overnight at 4◦C with rat monoclonal anti-CD41 antibody (MWReg30, 1:500, BD Pharmingen, USA), rabbit polyclonal anti-fibrin(ogen) antibody (1:500, gift from Dr. J. L. Degen, Cincinnati, OH, USA), and biotinylated anti-Aβ 1-16 (6E10, 1:1000, BioLegend, San Diego, CA, USA). Sections were then incu- bated for 1 hour with the following secondary antibodies; Cy3 goat anti-rat (1:500, Jackson Laboratories, Cambridge, UK), Alexa Fluor 594 donkey anti-rabbit (1:500, Thermo Fisher Scientific), and Alexa Fluor 647-conjugated streptavidin (1:250, Thermo Fisher Scientific), coun- terstained with DAPI, mounted and coverslipped with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA). Images were acquired using a HC PL Apo CS2 63×/1.4 oil objective on a Leica TCS SP8 confocal microscope (Leica Microsystems, Mannheim, Germany) at the CNIC Microscopy Unit. All procedures were carried out at RT unless otherwise specified, with thorough washes after steps.2.8 Statistical analysesBiodistribution and ROI data were analyzed using RStudio© (2025.05.1.513 Version, Posit Software, PBC, USA). Outliers were checked based on their Z-scores (values exceeding ± 3), although no data were excluded from the analyses as no outliers were found. Non- parametric statistics were applied when assumptions of normality and homoscedasticity were not accomplished after testing the data with Shapiro–Wilk’s and Levene’s tests, respectively. Therefore, to detect differences in the radiotracer uptake between groups, two-tailed two-sample T-tests or Mann–Whitney U analyses (p < 0.05) were performed. The magnitude of the differences between groups was evaluated using Cohen’s d as an effect size parameter. Furthermore, Pearson’s or Spearman’s correlation analyses were carried out to test the association between brain uptake and age. Data were corrected for injected radioactivity dose (ROI) and sex (ROI and biodistribution). Specifically, for [89Zr]-DFO-FBP whole brain ROI data obtained with the iterative histogram normalization method, Z-scores normalized to the respective WT group at each time point were calculated. This allowed us to compare the discriminatory power of the probe on the groups across time points. Additionally, PET images were evaluated by voxel-wise analysis using SPM12.49 Two-sample T-tests, with dose and sex as covariates, were performed to detect differences between groups. To account for multiple comparisons and enhance sensitivity to subtle effects, threshold-free cluster enhancement50 was applied, estimated using 10,000 permutations. Results were considered statistically significant at p < 0.05 corrected for False discovery rate (FDR). Only signif- icant clusters larger than 50 adjacent voxels were considered and represented as Cohen’s d maps overlaid on an MRI brain template. Additionally, the mean ± SD values of Cohen’s d maps for the statis- tically significant clusters are also provided to contextualize the mean effect size of the voxel-wise differences. ### Page 8 8 of 21 CERON ET AL.The association between human CD41 and fibrin in WB densito- metry measurements was performed by Spearman’s correlation using RStudio (p < 0.05). We first corrected the densitometric values of CD41 and fibrin normalized to tubulin levels (from three independent WB experiments) by sex, post mortem interval, and experimental batch. The residual values for each subject were averaged to ensure indepen- dent observations. Additionally, using these adjusted fibrin and CD41 values from the human post mortem cases, Spearman’s correlation anal- yses were performed with all available clinical variables shown in Table S1 in supporting information, while Mann–Whitney U tests were used to assess differences according to the presence of “Vascular Pathology” (as defined by BT-CIEN neuropathologists) 51,52 in RStudio (p < 0.05). Differences in CD41-positive platelet counts between human AD frontal cortex sections from cases with and without cerebral fibrin were assessed by Mann–Whitney U test. WB statistical analysis of mouse data was performed using RStudio following the same data screening protocol as for ROIs data. To ensure data independence, densitometric values of CD41 normalized to tubu- lin were averaged for each subject and analyzed using a two-tailed t-test comparing experimental (i.e., AD vs. WT) groups. Differences in CD41-positive platelet counts in AD versus WT mice were evaluated by two-tailed, two-sample t-test, with values of p< 0.05 considered statistically significant. All values are presented as mean ± SD, and the effect size of group differences was quantified using Cohen’s d.3 RESULTS 3.1 Fibrin imaging in AD miceTo evaluate the dynamics of cerebral fibrin imaging in TgCRND8 AD mice, our initial approach assessed the specific brain uptake of FBP directly labeled with 89Zr (i.e., [89Zr]Zr-DFO-FBP). The radioisotope’s 78.4-hour half-life allowed imaging the same animal during 5 consec- utive days (Figure 1A). This design enabled us to identify the uptake interval that provided the greatest discriminatory power between AD and WT groups based on brain radiotracer signal. Figure 1B shows [89Zr]Zr-DFO-FBP brain uptake across all time points, expressed as the z-score of the uptake ratio. Although no statistically significant differ- ences were observed between groups at any timepoint when values were normalized to a common, valid reference region that allows com- parison across all timepoints, the greatest difference between WT and AD occurred at 24 hours post-injection (AD mean normalized z-scores: baseline = -0.25, 24-hour = 0.49, 48-hour = 0.23, 72-hour = -0.38, 96-hour = -0.17), which led us to select this timepoint for further analysis. At 24 hours post-[89Zr]Zr-DFO-FBP injection, using data nor- malized by a data-driven method optimal for these cross-sectional comparisons, all examined ROIs showed significant AD-WT differences (Figure 1C and Table S2 in supporting information). The voxel-wise analysis identified a single statistically significant cluster indicating a widespread increase in radiotracer uptake across the brain (Figure 1D, Cohen’s d = 1.392 ± 0.343). In this sense, while preclinical PET enables detection of widespread pathological processes, its spatial resolution and partial volume effects constrain the ability to resolve highly focal microthrombi. Therefore, observed large clusters may represent the aggregation of multiple affected regions rather than uniform diffuse pathology, and caution should be taken when interpreting regional specificity. To enhance the clinical translatability of our approach, and since the 24-hour PET acquisition provided the best discrimination between AD and WT groups after [89Zr]Zr-DFO-FBP injection (Figure 1B), we developed a pre-targeting strategy based on 68Ga (half-life 67.8 minutes) to reduce radiation dose while improving signal-to-noise ratio. We administered the FBP-TCO 1 day prior to imaging, followed by injection of [68Ga]Ga-DOTA-TZ 2 hours prior to PET acquisition (Figure 2A). Administering FBP-TCO in advance allowed clearance of unbound probe, leaving only molecules specifically bound to their target (i.e., fibrin) when the radioligand ([68Ga]Ga-DOTA-TZ) was administered closer to imaging acquisition, thereby improving PET signal. We observed a clear [68Ga]Ga-DOTA-TZ signal emitted from the thrombus region in the carotid crush injury model used as C+, which was not present in animals operated but injected with saline (Figure 2B), confirming the specificity of the pre-targeting FBP-TCO+ [68Ga]Ga-DOTA-TZ strategy. We then evaluated differential brain uptake of the radiotracer between AD and WT mice, and also included a C- group based on the injection of DCys-FBP-TCO in AD mice to assess nonspecific tracer uptake. ROI analyses revealed a marked, widespread increase in tracer uptake across all examined brain regions in AD ver- sus WT, while no significant differences were observed for AD versus C-DCys or WT versus C-DCys (Figure 2C and Table S3 in supporting information). Voxel-wise analysis identified a single, statistically sig- nificant cluster spanning the entire brain, reflecting elevated tracer uptake in AD versus WT mice (Figure 2D, Cohen’s d = 0.741 ± 0.368), but no differences were found between AD and C-DCys mice (data not shown). However, ex vivo biodistribution, a much more sensitive measurement, showed significantly higher uptake in AD versus WT (Cohen’s d = 1.510, p < 0.001), in AD versus C-DCys (Cohen’s d = 0.688,p = 0.049), and in C-DCys versus WT (Cohen’s d = 0.838, p = 0.015) ani- mals (Figure 2E and Table S3 in supporting information), that remained markedly higher in the AD group at all ages compared to WT and C-DCys (Spearman’s ρ = 0.55, p = 0.023; Figure 2F and Table S4 in sup- porting information). These differences indicate specific fibrin‑related binding in AD mice that PET imaging could not fully resolve in vivo probably due to resolution power.3.2 Platelets in the AD procoagulant brainFBP preferentially binds newly formed thrombi rather than established clots,53 potentially underestimating the total cerebral clot burden in AD. We therefore sought an alternative and complementary throm- botic target to enhance PET signal and evaluated platelets as potential diagnostic markers for this cerebrovascular dysfunction. Since the spe- cific contribution of platelets to AD remains underdefined,14,23 we first quantified platelet content in brain tissue from AD patients and ### Page 9 CERON ET AL. 9 of 21F I G U R E 1 Fibrin PET imaging in TgCRND8 AD mice by a direct-labeling approach. The [89Zr]Zr-DFO-FBP probe enables in vivo detection of cerebral fibrin accumulation in TgCRND8 AD mice 24 hours after injection. (A) Study design. (B) Z-scores of [89Zr]Zr-DFO-FBP brain uptake (normalized to mean WT levels) in WT and AD mice over 5 consecutive days. The 24-hour time point shows maximal discrimination between groups. (C) PET ROI analyses across brain regions 24 hours post-injection comparing AD with WT mice (t-test results: ***p < 0.005, ****p < 0.001; Mann–Whitney: ####p < 0.001). (D) Voxel-based results shown as Cohen’s d-maps overlaid on a T2-weighted MRI, indicating significant increase in cerebral [89Zr]-DFO-FBP uptake in AD versus WT mice 24 hours post-injection. Color bar represents Cohen’s d-values for increased brain [89Zr]Zr-DFO-FBP uptake. Hemisphere labels: Right (R) and Left (L), k > 50 voxels, p < 0.05 (FDR-corrected). AD, Alzheimer’s disease; FBP, fibrin binding probe; FDR, false discovery rate; MRI, magnetic resonance imaging; PET, positron emission tomography; ROI, region of interest; WT, wild-type; [89Zr]Zr-DFO-FBP, zirconium-89 radiolabeled fibrin binding probe modified with desferrioxamine B. ### Page 10 10 of 21 CERON ET AL.F I G U R E 2 Fibrin PET imaging in TgCRND8 AD mice by a pre-targeting approach. The FBP-TCO + [68Ga]Ga-DOTA-TZ strategy enables in vivo detection of cerebral fibrin accumulation in TgCRND8 AD mice. (A) Study design. (B) Representative PET images of the carotid crush injury model (C+), showing radiotracer uptake in the injured carotid region of WT mice injected with FBP-TCO + [68Ga]Ga-DOTA-TZ. (C) PET ROI analyses across brain regions comparing the different experimental groups (t-test: **p < 0.01; Mann–Whitney: #p < 0.05, ##p < 0.01). (D) Voxel-based results shown as Cohen’s d-maps overlaid on a T2-weighted MRI, indicating significant increased cerebral [68Ga]Ga-DOTA-TZ uptake in AD versus WT mice. Color bar represents Cohen’s d-values for increased brain [68Ga]Ga-DOTA-TZ uptake. Hemisphere labels: Right (R) and Left (L), k > 50 voxels,p < 0.05 (FDR-corrected). (E) Ex vivo biodistribution studies showing post mortem brain retention of [68Ga]-DOTA-TZ measured by gamma-counting after PET acquisition (Mann–Whitney: #p < 0.05, ####p < 0.001) and (F) plotted as a function of age, showing a positive association in AD mice (Spearman’s ρ = 0.55, p = 0.023). AD, Alzheimer’s disease; C-DCys, negative control; FBP, fibrin binding probe; FDR, false discovery rate; MRI, magnetic resonance imaging; PET, positron emission tomography; ROI, region of interest; TCO, transcyclooctene; TZ, tetrazine; WT, wild-type; [68Ga]Ga-DOTA-TZ: gallium-68 radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated to tetrazine. ### Page 11 CERON ET AL. 11 of 21TgCRND8 AD mice. To this end, we evaluated platelet content by CD41 expression in post mortem frontal cortex tissue from AD patients and assessed its correlation with cerebral fibrin levels. WB analysis showed heterogeneity in the amount of CD41 across AD patients (Figure 3A and B) but higher CD41 levels were detected in AD samples with greater cerebral fibrin content, revealing a significant positive cor- relation (Figure 3C; Spearman’s ρ = 0.343, p = 0.033). This finding further underscores the complexity of AD pathology and indicates that platelet content may serve as an effective in vivo target of the AD- associated procoagulant state. Notably, half of AD patients exhibited abnormal insoluble cerebral fibrin levels by qualitative assessment of the WB shown in Figure 3A (i.e., 48.72%), consistent with our previ- ous findings in AD samples from an independent brain bank.8 We also performed exploratory analyses assessing whether the clinical vari- ables from these human post mortem cases (Table S1 in supporting information) were significantly associated with the AD-procoagulant phenotype. We did not find any significant association with bearing theApolipoprotein E4 allele, with medication or with comorbidities. How- ever, the levels of cerebral fibrin burden were significantly increased in those patients diagnosed with “Vascular Pathology” (Cohen’s d = 0.437,p < 0.001). These exploratory analyses should be interpreted with cau- tion, given the limited sample size (N = 39). Future studies in larger and specifically powered cohorts will be required to define the relation- ship between demographic factors, cerebral fibrin/CD41 burden, and cerebrovascular pathology in AD. To further characterize platelets in the human AD brain, we per- formed immunohistochemistry on frontal cortex post mortem human AD samples in a subset of AD cases with high levels of fibrin and com- pared them with cases lacking cerebral fibrin as determined by WB (Figure 3A). In AD patients with cerebral fibrin burden, CD41 staining was robust, with extensive immunoreactivity primarily intravascular, either occluding small capillaries or partially blocking larger ves- sels, whereas AD samples without cerebral fibrin showed minimal CD41 signal, with only a few scattered platelets across the brain sec- tion (Figure 3D; 21.38 ± 4.73 platelets/mm2 versus 10.66 ± 4.83 platelets/mm2 in AD cases with high or none cerebral fibrin burden, respectively; Cohen’s d = 2.24, p = 0.009). Interestingly, CD41 stain- ing co-localized with fibrin-positive areas in the frontal cortex of AD patients exhibiting a procoagulant state (Figure 3E). These results indi- cate that platelets are present in the subset of AD patients with a procoagulant state, underscoring their potential as biomarkers and therapeutic targets. Having identified increased platelet content in the subset of AD patients with cerebral fibrin deposition, we next examined whether this feature was also present in TgCRND8 mice, the AD model used for our in vivo PET imaging (Figures 1 and 2). WB analysis showed elevated CD41 levels in cortical and hippocampal TgCRND8 samples relative to age-matched WT littermates (Figure 4A) and quantification con- firmed a significant increase in AD mice (Figure 4B; Cohen’s d = 1.79,p = 0.015). To further characterize cerebral platelet accumulation in the AD mouse model, we performed CD41 immunohistochemistry on brain sections from WT and TgCRND8 AD mice. AD mice displayed abundant intravascular platelets, frequently stalling small capillar- ies in the cortex and hippocampus and occasionally near amyloid plaques, whereas WT mice exhibited only sparse platelets (Figure 4C; 5.69 ± 1.83 platelets/mm2 versus 3.30 ± 1.50 platelets/mm2 in TgCRND8 and WT mice, respectively; Cohen’s d = 1.36, p = 0.029). Interestingly, CD41 staining was found with fibrin(ogen)-positive thrombotic deposits across the cortex and hippocampus of TgCRND8 mice (Figure 4D), near amyloid plaques (Figure 4E).3.3 Platelet imagingThe increased platelet presence in the brains of AD patients with a procoagulant state (Figure 3) and TgCRND8 mice (Figure 4) supported the development of a suitable biomarker and prompted us to investi- gate the in vivo detection of platelet accumulation by PET imaging in this mouse model. Building on our previous imaging results, we directly employed a pre-targeting strategy using Thrombo-tag, consisting of [68Ga]Ga-IONPs and a CD41-specific antiplatelet antibody bound in vivo by click chemistry.43 The anti–CD41-TCO was injected the day before imaging to allow distribution and clearance of unbound anti- body, thereby maximizing the signal from target-bound platelets when [68Ga]Ga-IONP-TZ was administered 2 hours prior to PET acquisition (Figure 5A). As expected, PET images of the carotid crush injury model revealed a positive signal at the thrombotic site in animals injected with the full functional probe due to successful biorthogonal reaction, while control animals injected with saline showed no specific signal in the lesioned area (Figure 5B), hence demonstrating the performance of our pre- targeting approach. Consistent with the FBP results (Figure 2), ROI analyses showed a robust, widespread increase in Thrombo-tag uptake across all examined brain regions in AD mice relative to WT controls (Figure 5C and Table S5 in supporting information). Furthermore, the AD group showed statistically significant increases compared to C-IgG mice in all ROIs but cerebellum and thalamus, with the effect being most pronounced in the cortex and hippocampus, while no differences were observed between WT and C-IgG in any of the ROIs analyzed (Figure 5C and Table S5 in supporting information). Voxel-wise analysis identified a single, brain-wide, statistically significant cluster, indicat- ing consistently higher activity in AD versus WT mice (Figure 5C, Cohen’s d = 0.967 ± 0.162). When comparing AD versus C-IgG mice, voxel-wise analysis showed again a single cluster along the brain but more restricted to cortical and hippocampal areas (Figure 5D, Cohen’sd = 1.051 ± 0.246), supporting again the relevance of these regions in the AD procoagulant pathology. These in vivo data were further corroborated by ex vivo biodistribution measurements (Figure 6A and Table S5 in supporting information), which not only showed a signifi- cant increase in brain Thrombo-tag uptake in AD versus WT (Cohen’sd = 0.925, p = 0.001) or C-IgG (Cohen’s d = 0.858, p = 0.013) mice, but also displayed a positive association between age and Thrombo- tag uptake in AD mice (Spearman’s ρ = 0.823, p < 0.001, Figure 6B and Table S6 in supporting information). To further examine age-related patterns of Thrombo-tag uptake in vivo within each experimental group, we analyzed radiotracer uptake measured by PET in the whole ### Page 12 12 of 21 CERON ET AL.(A) (B) (C) (D) (E)F I G U R E 3 Platelet deposition in the human AD brain and correlation with the AD-associated cerebral fibrin burden. WB and immunohistochemistry analyses illustrate the accumulation of fibrin and platelet marker CD41 in the frontal cortex of post mortem samples from AD patients. (A) Representative WB of soluble (CD41) and insoluble (fibrin) protein extracts from the frontal cortex of AD patients (arrows point to the corresponding quantified band). Blots were re-probed with anti-tubulin antibody as loading control. Human platelet lysate and an in vitro-generated human fibrin clot were run in parallel as positive controls, respectively (C+). Each lane corresponds to an individual AD patient. (B) Combined violin and box plots showing the distributions of fibrin/tubulin and CD41/tubulin ratios from the WB quantification in panel A. Each dot represents an individual patient. The fibrin/tubulin ratio of one patient exceeded the y-axis scale (ratio = 68.11) and is not displayed in the violin ### Page 13 CERON ET AL. 13 of 21plot for better visualization. (C) Scatter plot showing the relationship between CD41 and fibrin WB levels in each AD patient, indicating a positive significant correlation (Spearman’s ρ = 0.343, p = 0.033). CD41/tubulin and fibrin/tubulin ratios from three independent WB experiments are represented as averaged residuals for each subject. N = 39 AD patients. (D) Representative CD41 immunohistochemistry images of paraffin-embedded frontal cortex sections from a subset of the AD patients used in (A) (CD41, brown; hematoxylin counterstaining nuclei, blue). Intravascular platelets are found in AD patients with cerebral fibrin deposition in WB analysis (A), partially occluding large vessels or blocking small capillaries. In contrast, CD41 staining shows only sporadic single platelets or punctate CD41 immunoreactivity in AD patients whose frontal cortex lacked detectable fibrin by WB (A). Scale bar, 25 μm. (E) Representative double immunostaining images of PFA-fixed frontal cortex sections showing CD41-positive cells (blue) co-localizing with fibrin (brown) in AD patients with cerebral fibrin. Scale bars, 25 μm and 50 μm. AD, Alzheimer’s disease; PFA, paraformaldehyde; WB, Western blot. brain, cortex and hippocampus ROIs as a function of age (Figure 6C and Table S6 in supporting information). In the AD group, Thrombo-tag uptake increased significantly with advancing age in the cortex (Spear- man’s ρ = 0.551, p = 0.034) and hippocampus (Pearson’s R = 0.727,p = 0.002), while no similar tendencies were found neither in WT nor in C-IgG animals. Together, these in vivo data demonstrate elevated Thrombo-tag specific cerebral uptake in TgCRND8 mice with a strong pathology-burden dependence.4 DISCUSSIONThe primary contribution of our study lies in the development of spe- cific PET imaging probes for detecting the procoagulant state in AD. We show that fibrin- and platelet-targeted probes present increased brain uptake in AD animals with a procoagulant state compared to controls, establishing the first in vivo detection of the AD-associated procoagulant environment (Graphical Abstract). We also provide evi- dence of significantly increased platelet accumulation in the AD brain concomitant with the AD’s procoagulant state, both in patients and in TgCRND8 mice. Together, these findings represent a significant step toward non-invasive diagnostic strategies for the AD-procoagulant state, with clear translational potential for clinical practice. In 2016, the AT(N) system was proposed as a neuropathological classification of AD based on Aβ deposition (A), tau pathology (T), and neurodegeneration (N).54 This framework led to a redefinition of AD from a clinical syndrome to a neuropathological construct,55 emphasizing the pivotal role of imaging and fluid biomarkers in AD research, diagnosis and therapy.55 Specifically, PET neuroimag- ing of Aβ and tau has been critical for AD diagnosis and staging, mapping temporospatial progression, and enabling disease-specific trials.56,57 More recently, the Alzheimer’s Association expanded the classification system to include inflammatory/immune mechanisms (I), vascular brain injury (V), and α-synucleinopathy (S),58 reflecting the aim to integrate AD’s multifactoriality in its conceptualization. Beyond Aβ and tau radiotracers, other PET probes are being developed for proteinopathies (e.g., α-synuclein, TDP-4357), for neuroinflamma- tion targeting active microglia (e.g., TSPO, cyclooxygenase, CSF-1) or astrogliosis (e.g., MAO-B, imidazol-2 binding site),59 and for synaptic disfunction/degeneration (e.g., SV2A,60 VAChT61). However, all these PET probes remain largely in preclinical phases,57,62 and the only neu- roimaging approved AD PET tracers are restricted to Aβ and tau, limiting current diagnostic capacity. Hence, deploy imaging strategies sensitive enough to detect widespread, potentially chronic cerebral microthrombi is essential. As reviewed by Stendahl et al,36 multiple radiotracers have been devel- oped for thrombus detection by nuclear imaging. Probes targeting fibrin,63–65 activated platelets,66–69 and factor XIIIa70 show promise for detecting focal, large-vessel thrombotic events. However, most of these probes are biased toward sites of active thrombosis,36,69,70 limit- ing detection of chronic or mature thrombi, and none has been com- prehensively evaluated in the diffuse prothrombotic milieu expected in AD. Direct comparison with our imaging approaches is not yet fea- sible, and head-to-head studies will be required to benchmark these PET probes in the AD-procoagulant context. Here, using fibrin- and platelet-targeted PET probes, we detected higher cerebral uptake in vivo in TgCRND8 mice in comparison with their WT littermates. Cortical and key subcortical regions (e.g., hippocampus) exhibited pronounced increases in radiotracer uptake, indicating substantial involvement of procoagulant mechanisms in areas critical for cogni- tion and affected early in AD.71,72 Consistent with reports of elevated fibrin(ogen) in these regions in AD human and murine tissue,8 our results demonstrate in vivo detection of this cerebrovascular dysfunc- tion. Importantly, probe uptake positively correlated with age only in AD mice, supporting that the PET signal tracks pathology progression rather than nonspecific aging. The consistent increase with two mech- anistically distinct tracers supports the specificity of our approach in detecting the AD procoagulant state. For clinical translation, platelet imaging may be preferable as platelets are predominantly intravascular in both human and mouse AD brain (Figures 3 and 4), whereas fibrin also shows strong intra- parenchymal staining8 that our FBP-PET approach likely misses. Sensitivity for fibrin imaging could be improved by BBB-penetrating fibrin probes, such as the recently reported proof-of-concept bispe- cific tracers73. Also, FBP uptake decrease as clots mature,53 whereas Thrombo-tag targets the constitutive platelet antigen CD41 and cap- tures both forming and chronic clots. Combined with FBP’s micromolar affinity,42 these features likely contribute to the lower in vivo sensi- tivity of the FBP-based pre-targeting PET approach and the lack of significant AD versus C-DCys brain differences by PET. In contrast, Thrombo-tag leverages a nanoparticle platform43 that enhances click- chemistry target engagement, likely consistent with its larger in vivo effect size. Cohen’s d > 0.8 are considered “large” effects,74 aligned with Thrombo-tag’s performance. While Aβ/tau PET typically yields very large effects (d≈2-3),75–79, neuroinflammation80,81 and synap- tic dysfunction60,61 PET tracers often show moderate yet meaningful ### Page 14 14 of 21 CERON ET AL.(A) (B) (C) (D) (E)F I G U R E 4 Platelet deposition in the mouse AD brain. WB and immunohistochemistry analyses show platelet accumulation in the cortex and hippocampus of AD mice. (A) Representative CD41 WB of soluble cortical and hippocampal protein extracts from WT and TgCRND8 AD mice. Blots were re-probed with anti-tubulin antibody as loading control. Mouse platelet lysate was included as positive control (C+). (B) Three different WB experiments were quantified and averaged values for each mouse plotted. CD41 levels were significantly increased in TgCRND8 AD brains compared to age-matched WT littermate controls (NAD = 6, NWT = 6; T-test: *p < 0.05). (C) Representative immunohistochemistry images showing numerous CD41-positive platelets (brown) obstructing small vessels or co-localizing with Aβ deposits (Thioflavin S counterstain, green) in the cortex and hippocampus of TgCRND8 AD mice. In contrast, corresponding regions from age-matched WT littermates display little to none CD41 ### Page 15 CERON ET AL. 15 of 21staining. (D) Representative double immunostaining images showing CD41-positive cells (blue) co-localizing with fibrin(ogen) (brown) in TgCRND8 AD mice, whereas WT mice show sparse fibrin(ogen) and CD41 staining. Scale bar, 25 μm. (E) Representative confocal images of triple immunofluorescence in the cortex of TgCRND8 mice show fibrin(ogen)-positive structures (red) associated with platelets (CD41, white) in the presence of Aβ (6E10, cyan). Scale bar, 10 μm. Aβ, amyloid-β; AD, Alzheimer’s disease; WB, Western blot; WT, wild-type. effects (d≈0.7–1.3, calculated from reported data). These comparisons underscore the strong discriminatory power of our probes and position Thrombo-tag as the leading biomarker candidate to detect a gener- alized cerebral procoagulant state in AD. Importantly, preclinical AβPET experience indicates that moderate-to-large regional differences in mice provide a robust in vivo readout of disease-relevant pathol- ogy and progression,82,83 and clinical Aβ PET demonstrates consistent regional retention across tracers/cohorts, supporting translational relevance for diagnosis and longitudinal follow-up.84,85 Accordingly, although our effect sizes are smaller than those typically reported for Aβ/tau tracers, they are comparable to established pathophysiology- targeted tracers and should be detectable in humans, especially in longitudinal designs. In this context, our study provides the first quantitative evidence of increased platelet accumulation in the human and mouse AD brain and its correlation with cerebral fibrin deposition. The literature on platelets in AD is controversial, likely reflecting their multifaceted nature and stage-dependent roles across the AD continuum.23 Most studies have focused on circulating platelets, whereas evidence of platelet presence within the AD brain, although reported in patients86 and mice,19,87 remains limited. Notably, no study has demonstrated a correlation between brain platelets and the increased cerebral fib- rin observed in AD, an association that would be expected a priori, given the well-established interplay between platelets and coagula- tion. In AD, however, platelets recruitment may further exacerbate the procoagulant milieu by promoting aggregation and fibrinogen binding, triggering coagulation pathways and further increasing local platelet levels, which may constitute an integral part of the thrombi formed in AD brains.8,9,88 Moreover, platelets may contribute to thrombus persistence in AD9 through local Aβ release, facilitat- ing Aβ–fibrin interactions that stiffen clots and exacerbate CAA- related vascular injury.19,86 Furthermore, elevated platelet activation associates with worse cognitive outcomes18 and fibrin has a well- established causal role in AD pathophysiology,23,30 including effects on cerebral hypoperfusion.25 Collectively, these data support a fibrin- platelet axis of high diagnostic relevance in AD. Here, we introduce a novel non-invasive neuroimaging strategy designed to detect this pathological process and ultimately enable personalized therapeutic interventions. Our strategy may help distinguish AD from other neurodegenera- tive conditions because fibrinogen’s involvement is particularly com- pelling: Aβ binds fibrinogen,10 promotes fibrinogen oligomerization,10 impairs fibrinolysis,11,12 and disruption of this interaction rescues thrombosis and cognitive decline in AD mice.89 The procoagulant phenotype is also linked to vascular Aβ deposition, as lowering fibrino- gen attenuates CAA9 and CAA-linked Aβ mutations show increased fibrinogen affinity.24 Thus, CAA may create focal vascular niches that favor Aβ–fibrinogen–platelet interactions, which our fibrin- and platelet-PET signals may partially reflect. We acknowledge that these tracers could detect thrombotic processes beyond AD; however, our readout is brain-restricted, reducing confounding by systemic thrombosis. Clinically, these PET measures should be interpreted alongside established AD biomark- ers (Aβ/tau/neurodegeneration PET and/or fluid-based biomarkers) to capture comprehensive profiling, patient stratification, and mechanism-guided therapeutic targeting, including anticoagulant, antiplatelet and/or fibrin immunotherapy when appropriate. This diagnostic strategy is particularly relevant because, although coagulation can be targeted therapeutically, cerebral fibrin burden varies widely across AD patients (Figure 3 and Cortes-Canteli et al8). Identifying those most likely to benefit is critical to maximize effi- cacy and minimize bleeding risk. Several anticoagulants and emerging antiplatelet therapies have shown potential to slow disease progres- sion in patients and AD mouse models.7,23 In parallel, fibrin-targeted immunotherapy is promising: a monoclonal antibody against fibrin’s pro-inflammatory epitope (without affecting coagulation) reduced neuroinflammation and provided neuroprotection in AD mice,32 and a higher-affinity humanized version is now in Phase 1 trials.33 Regard- less of the therapeutic modality, AD patients differ in cerebral fibrin burden, highlighting the importance of the diagnostic tool described here. Finally, we must acknowledge several limitations of our study. First, FBP is a small peptide with high clearance rate via the uri- nary system, which may have resulted in partial loss of specific signal during imaging. Second, IONPs exhibit a long half-life in the body, particularly in the liver as the main organ of elimination. However, these nanoparticles have been shown to be safe and non-toxic,90 and have received approval by the United States Food and Drug Administration for various medical applications.91,92 Third, amyloid overexpression in TgCRND8 mice might amplify fibrin–platelet inter- actions, consistent with evidence that Aβ binds fibrinogen10 and that platelets are the main source of Aβ in blood.15 However, we expect similar fibrin and platelet PET signals in tau-based mod- els given that fibrinogen interacts with tau enhancing cytotoxicity, tau phosphorylation/aggregation and neuronal dysfunction,93 and tau hyperphosphorylation/deposition interacts with components of the AD-disrupted BBB.94 Finally, we acknowledge that disease-related radiotracer uptake thresholds must be established in subsequent stud- ies to enable the clinical translation of this approach as a diagnostic biomarker. In conclusion, this study provides the first in vivo neuroimaging approach to identify the AD-associated procoagulant environment through the development of highly specific PET imaging biomark- ers. These results not only advance our understanding of the ### Page 16 16 of 21 CERON ET AL.F I G U R E 5 Platelet PET imaging in the brain of TgCRND8 AD mice by a pre-targeting approach. Thrombo-tag (i.e., anti–CD41-TCO +[68Ga]Ga-IONP-TZ) enables in vivo cerebral detection of platelet accumulation in TgCRND8 AD mice. (A) Study design. (B) Representative PET images of the carotid crush injury model (C+) showing high radiotracer uptake in the injured carotid region of WT mice injected with the anti–CD41-TCO + [68Ga]Ga-IONP-TZ. (C) PET ROI analyses across brain regions comparing AD versus WT mice (t-test: *p < 0.05, ****p < 0.001; Mann–Whitney: #p < 0.05, ##p < 0.01, ####p < 0.001). Voxel-based results shown as Cohen’s d-maps overlaid on a T2-weighted MRI, indicating significant increases in [68Ga]Ga-IONP-TZ uptake in AD versus WT (D) and AD versus C-IgG (E) mice. Color bar represents Cohen’s d-values for increased cerebral Thrombo-tag uptake. Hemisphere labels: Right (R) and Left (L), k > 50 voxels, p < 0.05 (FDR-corrected). AD, Alzheimer’s disease; C-IgG, negative control; FDR, false discovery rate; MRI, magnetic resonance imaging; PET, positron emission tomography; ROI, region of interest; TCO, transcyclooctene; TZ, tetrazine; WT, wild-type; [68Ga]Ga-IONP-TZ: tetrazine functionalized iron oxide nanoparticles doped with 68-gallium. ### Page 17 CERON ET AL. 17 of 21(A) (B) (C)F I G U R E 6 Age-related platelet radiotracer brain uptake in AD mice. (A) Ex vivo biodistribution studies showing post mortem brain retention of Thrombo-tag measured by gamma-counting after PET acquisition (Mann–Whitney results: #p < 0.05, ##p < 0.01) (B) Ex vivo measurements of the radiotracer uptake in the brain as a function of age, showing a strong positive correlation in AD mice (Spearman’s ρ = 0.823, p < 0.001). (C) Correlation analyses between age and in vivo Thrombo-tag PET signal in the whole brain (left), cortex (middle) and hippocampus (right) showing a significant positive association in AD mice (cortex: Spearman’s ρ = 0.551, p = 0.034; hippocampus: Pearson’s R = 0.727, p = 0.002). AD, Alzheimer’s disease; C-IgG, negative control; PET, positron emission tomography. cerebrovascular contributions to AD but also open the door to non- invasive diagnostic approaches with tangible translational potential for patient stratification and therapeutic guidance.ACKNOWLEDGMENTSThe authors especially acknowledge the contributions of Dr. Irene Fernández-Barahona during the initial steps of this research, and Dr. Peter Caravan for providing FBP for the initial exper- iments. The microscopy experiments were carried out at the CNIC Microscopy and Dynamic Imaging Unit, co-funded by MCIN/AEI/10.13039/501100011033 and by FEDER, ‘A way of making Europe’ (#ICTS-2018-04-CNIC-16). We are also grateful to the CNIC’s Histopathology Core and to the imaging technicians who facilitated image acquisition. We gratefully acknowledge the patients and the Biobank Banco de Tejidos CIEN (PT17/0015/0014) integrated in the Spanish National Biobanks Network for their collaboration, and, particularly Alberto Rábano and Laura Saiz for their help with the neuropathological diagnoses and associated data. This is an EU Joint Program – Neurodegenerative Disease Research (JPND) project (JPND2020-568-025), supported through the ISCIII (AC20/00091 and AC20/00077) under the aegis of JPND - www.jpnd. eu. Dr. Cortes-Canteli was supported by a Miguel Servet type II con- tract (Instituto de Salud Carlos III (ISCIII), CPII21/00007; co-funded by the ESF+). Dr. Casquero-Veiga is supported by BrightFocus Foundation Postdoctoral Fellowship Program in Alzheimer’s Disease Research (A2023012F), and grant JDC2022-048922-I funded by Ministerio de Ciencia e Innovación (MCIN) MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. Dr. Salinas is sup- ported by a Ramón y Cajal contract (RYC2023-043741-I, Ministerio de Ciencia, Innovación y Universidades -MICIU). Dr. Cortes-Canteli, Dr. Pérez-Medina, Dr. Desco, Dr Herranz and Dr. Morcillo were supported by the MCIN network DIAMOND (RED2022-134299- T). We also acknowledge support from the Nanomedicine CSIC Hub (ref.202180E048) and the PTI-NEUROAGING (CSIC, Spain). This project used equipment from the Infraestructuras Científicas y Técnicas Singulares (ICTS) infrastructure Red Distribuida de Imagen ### Page 18 18 of 21 CERON ET AL.Biomédica (ReDIB), Infraestructura de Imagen Traslacional Avanzada(TRIMA@CNIC) node, MICIU. Grant ICT2021-006950 funded by MICIU and the European Union NextGeneration EU/PRTR. This research was also partially funded by grants awarded to Dr. Cortes- Canteli (PID2024-157521OB-I00 and CNS2023-144316), Dr. Moro (PID2022-140616OB-I00) and Dr. Herranz (PDC2022-133493-100) from MICIU/AEI /10.13039/501100011033 / FEDER and European Union NextGenerationEU/PRTR. Dr. Rubio and Dr. Desco were supported by Comunidad de Madrid, grant S2022/BMD-7403 Red Madrileña de Nanomedicina en Imagen Molecular (RENIM-CM). The CNIC is supported by the ISCIII, the MICIU and the Pro CNIC Founda- tion, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033).CONFLICT OF INTEREST STATEMENTAuthor disclosures are available in the Supporting Information.DISCLOSURESThe authors declare no competing financial interests.CONSENT STATEMENTAll post mortem human samples were provided by the Biobank Banco de Tejidos CIEN (BT-CIEN), integrated in the Spanish National Biobanks Network. All samples were obtained under informed consent from the donor or, when this was not possible, from a legal representative or next of kin and they were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees.ORCIDCarlos Ceron https://orcid.org/0000-0002-9993-8095Marta Casquero-Veiga https://orcid.org/0000-0003-0859-9495Nicolás Lamanna-Rama https://orcid.org/0000-0002-3450-566XAlberto Fernández-Pena https://orcid.org/0000-0002-2844-2965Nancy Olazagoitia https://orcid.org/0009-0002-2454-0274Aitor Herraiz https://orcid.org/0000-0002-1018-6692María Isabel González https://orcid.org/0000-0003-0666-4871María Muñoz-Hernando https://orcid.org/0000-0002-2980-7233Alejandro Ruperti-Repilado https://orcid.org/0009-0009-4537- 6961Eduardo Romero-Sanz https://orcid.org/0000-0003-1347-1947Miguel Ángel Morcillo https://orcid.org/0000-0002-1984-5834Carlos Pérez-Medina https://orcid.org/0000-0002-6011-0629Maria Angeles Moro https://orcid.org/0000-0003-1010-8237Gonzalo Villaverde https://orcid.org/0000-0003-2065-0417Jorge Rubio https://orcid.org/0000-0002-1785-5844Jose Fernandez-Ferro https://orcid.org/0000-0003-1172-0153Manuel Desco https://orcid.org/0000-0003-0989-3231Fernando Herranz https://orcid.org/0000-0002-3743-0050Beatriz Salinas https://orcid.org/0000-0001-9388-5917Valentin Fuster https://orcid.org/0000-0002-9043-9986Marta Cortes-Canteli https://orcid.org/0000-0001-8802-4338REFERENCES1. World Health Organization. Dementia. 2025. Accessed October 12, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia 2. Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125. doi:10.1016/S2468-2667(21)00249-8 3. Deture MA, Dickson DW. The neuropathological diagno- sis of Alzheimer’s disease. Mol Neurodegener. 2019;14(1):32. doi:10.1186/s13024-019-0333-5 4. Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research. Biomedicines. 2019;7(4):97. doi:10.3390/biomedicines7040097 5. Stelzmann RA, Norman Schnitzlein H, Reed Murtagh F. An english translation of alzheimer’s 1907 paper, ‘’über eine eigenartige erkankung der hirnrinde. Clinical Anatomy. 1995;8(6):429-431. doi:10.1002/ca.980080612 6. Cortes-Canteli M, Iadecola C. Alzheimer’s Disease and Vascular Aging.J Am Coll Cardiol. 2020;75(8):942-951. doi:10.1016/j.jacc.2019.10.062 7. Toribio-Fernandez R, Ceron C, Tristão-Pereira C, et al. Oral antico- agulants: a plausible new treatment for Alzheimer’s disease?. Br J Pharmacol. 2024;181(6):760-776. doi:10.1111/bph.16032 8. Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fib- rin deposited in the Alzheimer’s disease brain promotes neuronal degeneration. Neurobiol Aging. 2015;36(2):608-617. doi:10.1016/j. neurobiolaging.2014.10.030 9. Cortes-Canteli M, Paul J, Norris EH, et al. Fibrinogen and β-amyloid association alters thrombosis and fibrinolysis: a possible contribut- ing factor to Alzheimer’s disease. Neuron. 2010;66(5):695-709. doi:10. 1016/j.neuron.2010.05.014 10. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer’s disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A. 2010;107(50):21812-21817. doi:10.1073/pnas.1010373107 11. Zamolodchikov D, Strickland S. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood. 2012;119(14):3342-3351. doi:10.1182/blood-2011-11-389668 12. Zamolodchikov D, Berk-Rauch HE, Oren DA, et al. Biochemical and structural analysis of the interaction between β-amyloid and fibrinogen. Blood. 2016;128(8):1144-1151. doi:10.1182/blood-2016- 03-705228 13. Kucheryavykh LY, Dávila-Rodríguez J, Rivera-Aponte DE, et al. Platelets are responsible for the accumulation of β-amyloid in blood clots inside and around blood vessels in mouse brain after thrombo- sis. Brain Res Bull. 2017;128:98-105. doi:10.1016/j.brainresbull.2016. 11.008 14. Canobbio I, Guidetti GF, Torti M. Platelets in neurological dis- orders. Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: An Update. Springer International Publishing; 2017:513-530. doi:10.1007/978-3-319- 47462-5_35 15. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the pri- mary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun. 1995;213(1):96-103. doi:10.1006/bbrc.1995.2103 16. Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. Role of amy- loid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease. Front Cell Neurosci. 2015;9:65. doi:10.3389/fncel. 2015.00065 17. Beura SK, Dhapola R, Panigrahi AR, Yadav P, Reddy DH, Singh SK. Redefining oxidative stress in Alzheimer’s disease: targeting platelet reactive oxygen species for novel therapeutic options. Life Sci. 2022;306:120855. doi:10.1016/j.lfs.2022.120855 18. Stellos K, Panagiota V, Kögel A, Leyhe T, Gawaz M, Laske C. Predictive value of platelet activation for the rate of cognitive ### Page 19 CERON ET AL. 19 of 21decline in Alzheimers disease patients. J Cereb Blood Flow Metab. 2010;30(11):1817-1820. doi:10.1038/jcbfm.2010.140 19. Gowert NS, Donner L, Chatterjee M, et al. Blood platelets in the pro- gression of alzheimer’s disease. PLoS One. 2014;9(2):e90523. doi:10. 1371/journal.pone.0090523 20. Yubolphan R, Pratchayasakul W, Koonrungsesomboon N, Chattipakorn N, Chattipakorn SC. Potential links between platelets and amyloid-β in the pathogenesis of Alzheimer’s disease: evi- dence from in vitro, in vivo, and clinical studies. Exp Neurol. 2024;374:114683. doi:10.1016/j.expneurol.2024.114683 21. Platelets HC. Their potential contribution to the generation of beta-amyloid plaques in Alzheimer’s disease. Curr Neurovasc Res. 2017;14(3):290-298. doi:10.2174/1567202614666170705150535 22. Jarre A, Gowert NS, Donner L, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell Signal. 2014;26(9):2040-2050. doi:10.1016/j.cellsig.2014. 05.019 23. Casquero-Veiga M, Ceron C, Cortes-Canteli M. Alzheimer’s disease and vascular biology – a focus on the procoagulant state. Curr Opin Cell Biol. 2025;95:102528. doi:10.1016/j.ceb.2025.102528 24. Cajamarca SA, Norris EH, van der Weerd L, Strickland S, Rosenwald J. Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen.Proc Natl Acad Sci U S A. 2020;25(117):14482-14492. doi:10.1073/ pnas.1921327117 25. Cortes-Canteli M, Kruyer A, Fernandez-Nueda I, et al. Long-term dabigatran treatment delays alzheimer’s disease pathogenesis in the TgCRND8 mouse model. J Am Coll Cardiol. 2019;74(15):1910-1923. doi:10.1016/j.jacc.2019.07.081 26. Simões-Pires EN, Torrente D, Singh P, Strickland S, Norris EH. Syn- ergistic effects of the Aβ/fibrinogen complex on synaptotoxicity, neuroinflammation, and blood–brain barrier damage in Alzheimer’s disease models. Alzheimers Dement. 2025;21(5):e70119. doi:10.1002/ alz.70119 27. Merlini M, Rafalski VA, Rios Coronado PE, et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer’s disease model. Neuron. 2019;101(6):1099-1108. doi:10. 1016/j.neuron.2019.01.014 28. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltra- tion and microglial reactivity in inflamed Alzheimer’s disease brain.J Cell Mol Med. 2009;13(9 A):2911-2925. doi:10.1111/j.1582-4934. 2008.00434.x 29. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neu- rovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J Exp Med. 2007;204(8):1999-2008. doi:10.1084/ jem.20070304 30. Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19(5):283-301. doi:10.1038/nrn.2018.13 31. Beura SK, Dhapola R, Panigrahi AR, et al. Antiplatelet drugs: potential therapeutic options for the management of neurodegenerative dis- eases. Med Res Rev. 2023;43(6):1835-1877. doi:10.1002/med.21965 32. Ryu JK, Rafalski VA, Meyer-Franke A, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegen- eration. Nat Immunol. 2018;19(11):1212-1223. doi:10.1038/s41590- 018-0232-x 33. Kantor AB, Akassoglou K, Stavenhagen JB. Fibrin-targeting immunotherapy for dementia. J Prev Alzheimers Dis. 2023; 10(4):647-660. doi:10.14283/jpad.2023.105 34. Franceschi AM, Keir G, Benzinger TLS, et al. Clinical role of brain PET in Alzheimer disease in the era of disease-modifying therapies. AJNR Am J Neuroradiol. 2025;46(8):1521-1527. doi:10.3174/ajnr.A8738 35. Wang X, Ziegler M, Mcfadyen JD, Peter K. Molecular imaging of arte- rial and venous thrombosis. Br J Pharmacol. 2021;178(21):4246-4269. doi:10.1111/bph.15635 36. Stendahl JC, Kwan JM, Pucar D, Sadeghi MM. Radiotracers to address unmet clinical needs in cardiovascular imaging, part 2: inflammation, fibrosis, thrombosis, calcification, and amyloidosis imaging. J Nucl Med. 2022;63(7):986-994. doi:10.2967/jnumed.121.263507 37. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276(24):21562- 21570. doi:10.1074/jbc.M100710200 38. du Sert NP, Hurst V, Ahluwalia A, et al. The arrive guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;177(16):3617-3624. doi:10.1371/journal.pbio.3000410 39. Herraiz A, Rodríguez-San-Pedro A, Casquero-Veiga M, et al. A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelator. npj Imaging. 2026;4(1):8. doi:10.1038/s44303-026-00142-1 40. Oliveira BL, Blasi F, Rietz TA, Rotile NJ, Day H, Caravan P. Multi- modal molecular imaging reveals high target uptake and specificity of 111In-and 68Ga-labeled fibrin-binding probes for thrombus detection in rats. J Nucl Med. 2015;56(10):1587-1592. doi:10.2967/jnumed.115. 160754 41. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radi- olabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl- desferrioxamine. Nat Protoc. 2010;5(4):739-743. doi:10.1038/nprot. 2010.13 42. Kolodziej AF, Nair SA, Graham P, et al. Fibrin specific peptides derived by phage display: characterization of peptides and conju- gates for imaging. Bioconjug Chem. 2012;23(3):548-556. doi:10.1021/ bc200613e 43. Adrover JM, Pellico J, Fernández-Barahona I, et al. Thrombo-tag, an in vivo formed nanotracer for the detection of thrombi in mice by fast pre-targeted molecular imaging. Nanoscale. 2020;12(45):22978- 22987. doi:10.1039/d0nr04538a 44. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 3rd ed.. Academic Press (Elsevier); 2007. 45. Pascau J, Vaquero JJ, Abella M, Cacho R, Lage E, Desco M. Multi- modality workstation for small animal image visualization and analysis.Scientific Papers Mol Imaging Biol. 2006;8:97-98. 46. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. Neuroimage. 2012;62(2):782-790. doi:10.1016/j.neuroimage. 2011.09.015 47. López-González FJ, Silva-Rodríguez J, Paredes-Pacheco J, et al. Intensity normalization methods in brain FDG-PET quantification.Neuroimage. 2020;222:117229. doi:10.1016/j.neuroimage.2020. 117229 48. Yakushev I, Landvogt C, georg BuchholzH, et al. Choice of refer- ence area in studies of Alzheimer ’ s disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res Neuroimag- ing. 2008;164(2):143-153. doi:10.1016/j.pscychresns.2007.11.004 49. Wellcome Trust Centre for Neuroimaging. SPM12 - Statistical Para- metric Mapping. 2012. Accessed October 13, 2025. https://www.fil. ion.ucl.ac.uk/spm/software/spm12/ 50. Smith S, Nichols T. Threshold-free cluster enhancement: address- ing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44(1):83-98. doi:10.1016/j. neuroimage.2008.03.061 51. Skrobot OA, Attems J, Esiri M, et al. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovas- cular pathology to cognitive impairment. Brain. 2016;139(11):2957- 2969. doi:10.1093/brain/aww214 52. Deramecourt V, Slade JY, Oakley BAE, et al. Staging and natu- ral history of cerebrovascular pathology in dementia. Neurology. 2012;78(14):1043-1050. doi:10.1212/WNL.0b013e31824e8e7f 53. Blasi F, Oliveira BL, Rietz TA, et al. Multisite thrombus imaging and fibrin content estimation with a single whole-body PET scan in rats. ### Page 20 20 of 21 CERON ET AL.Arterioscler Thromb Vasc Biol. 2015;35(10):2114-2121. doi:10.1161/ ATVBAHA.115.306055 54. Jack CR, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. 55. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research frame- work: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018 56. Cohen AD, Villemagne VL. A brief history of Aβ imaging. Alzheimers Dement. 2025;21(5):e70291. doi:10.1002/alz.70291 57. Higuchi M, Tagai K, Takahata K, Endo H. Advances in PET imaging of protein aggregates associated with neurodegenerative disease. Nat Rev Neurol Nat Res. 2025;21(9):506-522. doi:10.1038/s41582-025- 01126-2 58. Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diag- nosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement. 2024;20(8):5143-5169. doi:10.1002/ alz.13859 59. Lee N, Choi JY, Ryu YH. The development status of PET radio- tracers for evaluating neuroinflammation. Nucl Med Mol Imaging. 2024;58(4):160-176. doi:10.1007/s13139-023-00831-4 60. Mecca AP, Chen MK, O’Dell RS, et al. In vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET.Alzheimers Dement. 2020;16(7):974-982. doi:10.1002/alz.12097 61. Aghourian M, Legault-Denis C, Soucy JP, et al. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22(11):1531-1538. doi:10.1038/ mp.2017.183 62. Ottoy J, Owsicki N, Bilgel M, et al. Recent advances in neuroimag- ing of Alzheimer’s disease and related dementias. Alzheimers Dement. 2025;21(9):e70648. doi:10.1002/alz.70648 63. Oliveira BL, Caravan P. Peptide-based fibrin-targeting probes for thrombus imaging. Dalton Trans. 2017;46(42):14488-14508. doi:10. 1039/c7dt02634j 64. Ciesienski KL, Yang Y, Ay I, et al. Fibrin-targeted PET probes for the detection of thrombi. Mol Pharm. 2013;10(3):1100-1110. doi:10. 1021/mp300610s 65. Ay I, Blasi F, Rietz TA, et al. In vivo molecular imaging of thrombo- sis and thrombolysis using a fibrin-binding positron emission tomo- graphic probe. Circ Cardiovasc Imaging. 2014;7(4):697-705. doi:10. 1161/CIRCIMAGING.113.001806 66. Lohrke J, Siebeneicher H, Berger M, et al. 18F-GP1, a novel PET tracer designed for high-sensitivity, low-background detection of thrombi. J Nucl Med. 2017;58(7):1094-1099. doi:10.2967/jnumed.116.188896 67. Bayer Healthcare Pharmaceuticals. 8F GP1 At a glance. October 30, 2021. https://adisinsight.springer.com/drugs/800041626 68. Chae SY, Kwon TW, Jin S, et al. A phase 1, first-in-human study of 18 F-GP1 positron emission tomography for imaging acute arte- rial thrombosis. EJNMMI Res. 2019;9(1):3. doi:10.1186/s13550-018- 0471-8 69. Kim C, Lee JS, Han Y, et al. Glycoprotein IIb/IIIa receptor imaging with 18 F-GP1 PET for acute venous thromboembolism: an open-label, non- randomized, phase 1 study. J Nucl Med. 2019;60(2):244-249. doi:10. 2967/jnumed.118.212084 70. Andrews JPM, Portal C, Walton T, et al. Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer. Eur Heart J Cardiovasc Imaging. 2020;21(6):673-682. doi:10.1093/ehjci/ jez207 71. Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer’s disease: a review.3 Biotech. 2022;12(2):55. doi:10.1007/s13205-022-03123-4 72. Igarashi KM. Entorhinal cortex dysfunction in Alzheimer’s disease.Trends Neurosci. 2023;46(2):124-136. doi:10.1016/j.tins.2022.11.006 73. Sehlin D, Aguilar X, Cortés-Canteli M, Syvänen S. Lopes van den Broek S. Brain-penetrating peptide and antibody radioligands for proof-of-concept PET imaging of fibrin in Alzheimer’s disease. EJN- MMI Radiopharm Chem. 2025;10(1):59. doi:10.1186/s41181-025- 00383-2 74. Cohen J. Statistical Power Analysis for the Behavioral Sciences Second Edition. Lawrence Erlbaum Associates, Publishers; 1988. Second. 75. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s dis- ease. Eur J Nucl Med Mol Imaging. 2012;39(6):983-989. doi:10.1007/ s00259-012-2088-x 76. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F- florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210-1217. doi:10.2967/jnumed.111.089730 77. Vandenberghe R, Adamczuk K, Dupont P, Van LaereK, Chételat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin. 2013;2(1):497-511. doi:10. 1016/j.nicl.2013.03.014 78. Mohammadi Z, Alizadeh H, Marton J, Cumming P. The sensitivity of tau tracers for the discrimination of Alzheimer’s disease patients and healthy controls by PET. Biomolecules MDPI. 2023;13(2):290. doi:10. 3390/biom13020290 79. Mueller A, Bullich S, Barret O, et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in- humans study. J Nucl Med. 2020;61(6):911-919. doi:10.2967/jnumed. 119.236224 80. Kreisl WC, Lyoo CH, Liow JS, et al. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging. 2016;44:53-61. doi:10.1016/j.neurobiolaging.2016.04.011 81. Villemagne VL, Harada R, Doré V, et al. Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer disease spectrum. J Nucl Med. 2022;63(10):1560-1569. doi:10.2967/jnumed.121.263255 82. Manook A, Yousefi BH, Willuweit A, et al. Small-animal PET imaging of amyloid-beta plaques with [ 11c]PiB and its multi-modal valida- tion in an APP/PS1 mouse model of Alzheimer’s disease. PLoS One. 2012;7(3):e31310. doi:10.1371/journal.pone.0031310 83. Rominger A, Brendel M, Burgold S, et al. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing swedish mutantβ-Amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54(7):1127-1134. doi:10.2967/jnumed.112.114660 84. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40(1):104-114. doi:10.1007/s00259-012- 2237-2 85. Younes K, Johns E, Young CB, et al. Amyloid PET predicts longitudi- nal functional and cognitive trajectories in a heterogeneous cohort.Alzheimers Dement. 2025;21(3):e70075. doi:10.1002/alz.70075 86. Kniewallner KM, Ehrlich D, Kiefer A, Marksteiner J, Humpel C. Platelets in the Alzheimer’s disease brain: do they play a role in cere- bral amyloid angiopathy?. Curr Neurovasc Res. 2015;12(1):4-14. doi:10. 2174/1567202612666150102124703 87. Kniewallner KM, de Sousa DMB, Unger MS, Mrowetz H, Aigner L. Platelets in amyloidogenic mice are activated and invade the brain.Front Neurosci. 2020;14:129. doi:10.3389/fnins.2020.00129 88. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer’s disease. J Alzheimers Dis. 2012;32(3):599-608. doi:10.3233/JAD-2012-120820 89. Ahn HJ, Glickman JF, Poon KL, et al. A novel Aβ-fibrinogen inter- action inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J Exp Med. 2014;211(6):1049-1062. doi:10. 1084/jem.20131751 90. Pellico J, Fernández-Barahona I, Benito M, et al. Unambiguous detection of atherosclerosis using bioorthogonal nanomaterials.Nanomedicine. 2019;17:26-35. doi:10.1016/j.nano.2018.12.015 91. Cortajarena AL, Ortega D, Ocampo SM, et al. Engineering iron oxide nanoparticles for clinical settings. Nanobiomedicine (Rij). 2014;1:2. doi:10.5772/58841 ### Page 21 CERON ET AL. 21 of 2192. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10-29. doi:10.1002/btm2.10003 93. Wen T, Meng L, Liu H, et al. Fibrinogen-tau aggregates exacerbate tau pathology and memory deficits in Alzheimer’s disease model mice. Neurosci Bull. 2025;41(7):1246-1260. doi:10.1007/s12264-025- 01366-8 94. Huang C, Wei Z, Zheng N, et al. The interaction between dysfunc- tion of vasculature and tauopathy in Alzheimer’s disease and related dementias. Alzheimers Dement. 2025;21(2):e14618. doi:10.1002/alz. 14618SUPPORTING INFORMATIONAdditional supporting information can be found online in the Support- ing Information section at the end of this article.How to cite this article: Ceron C, Casquero-Veiga M, Lamanna-Rama N, et al. Unveiling the procoagulant state in Alzheimer’s disease: A novel PET imaging strategy. Alzheimer’s Dement. 2026;22:e71652. https://doi.org/10.1002/alz.71652